Boston Scientific Corp. has inked an agreement to acquire the rest of Cryterion Medical Inc. it does not own for $202 million in up-front cash. The attraction of Cryterion, of Carlsbad, Calif., is the development of a single-shot cryoablation platform for the treatment of atrial fibrillation (AF). Marlborough, Mass.-based Boston Scientific noted that it has invested in Cryterion since its 2016 inception. Read More
